Overview

A Study to Investigate the Efficacy and Safety of Lusutrombopag (S-888711) Tablets Administered to Adults With Immune Thrombocytopenia (ITP)

Status:
Terminated
Trial end date:
2010-11-24
Target enrollment:
Participant gender:
Summary
The primary objective of this study was to assess the efficacy of 3 dose levels of lusutrombopag (0.5 mg, 0.75 mg, and 1.0 mg) and placebo on platelet count.
Phase:
Phase 2
Details
Lead Sponsor:
Shionogi